Corcept Therapeutics Incorporated (CORT) Earnings History
Annual and quarterly earnings data from 2003 to 2025
Loading earnings history...
CORT EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CORT Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 98.3% | 5.9% | 13.1% |
| 2024 | 98.4% | 20.3% | 20.7% |
| 2023 | 98.7% | 22.2% | 22.0% |
| 2022 | 98.7% | 28.0% | 25.2% |
| 2021 | 98.6% | 34.0% | 30.7% |
Download Data
Export CORT earnings history in CSV or JSON format
Free sign-in required to download data
Corcept Therapeutics Incorporated (CORT) Earnings Overview
As of May 6, 2026, Corcept Therapeutics Incorporated (CORT) reported trailing twelve-month net income of $48M, reflecting -33.3% year-over-year growth. The company earned $0.46 per diluted share over the past four quarters, with a net profit margin of 13.1%.
Looking at the long-term picture, CORT's 5-year EPS compound annual growth rate (CAGR) stands at -0.7%, signaling declining earnings. The company achieved its highest annual net income of $140M in fiscal 2024.
Corcept Therapeutics Incorporated maintains positive profitability with a gross margin of 98.3%, operating margin of 5.9%, and net margin of 13.1%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including INVA ($504M net income, 63.8% margin), HRMY ($159M net income, 18.3% margin), SUPN (-$29M net income, -5.4% margin), CORT has room to improve margins relative to the peer group. Compare CORT vs INVA →
CORT Earnings vs Peers
Earnings metrics vs comparable public companies
CORT Historical Earnings Data (2003–2025)
23 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $100M | -28.7% | $45M | $0.82 | 13.1% | 5.9% |
| 2024 | $140M | +31.6% | $137M | $1.23 | 20.7% | 20.3% |
| 2023 | $106M | +4.7% | $107M | $0.94 | 22.0% | 22.2% |
| 2022 | $101M | -9.9% | $113M | $0.87 | 25.2% | 28.0% |
| 2021 | $113M | +6.1% | $124M | $0.89 | 30.7% | 34.0% |
| 2020 | $106M | +12.6% | $128M | $0.85 | 30.0% | 36.2% |
| 2019 | $94M | +24.9% | $112M | $0.77 | 30.7% | 36.4% |
| 2018 | $75M | -41.6% | $89M | $0.60 | 30.0% | 35.6% |
| 2017 | $129M | +1486.3% | $53M | $1.04 | 81.1% | 33.2% |
| 2016 | $8M | +227.0% | $10M | $0.07 | 10.0% | 12.5% |
See CORT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CORT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CORT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCORT — Frequently Asked Questions
Quick answers to the most common questions about buying CORT stock.
Is CORT growing earnings?
CORT EPS fell to $0.46, with earnings declining -33.3%. This contrasts with the 5-year CAGR of -0.7%. TTM net income dropped to $48M.
What are CORT's profit margins?
Corcept Therapeutics Incorporated net margin is +13.1%, with operating margin at +5.9%. Margins sit within typical range for the sector.
How consistent are CORT's earnings?
CORT earnings data spans 2003-2025. The declining earnings trend is -33.3% YoY. Historical data enables comparison across business cycles.